Bachem Holding AG (BANB.SW)
Swiss · CHF · Healthcare · Biotechnology
CHF 83.05 (+0.24%) as of
Key statistics
- Market cap
- 6.22B
- P/E (TTM)
- 41.94
- Forward P/E
- 26.97
- EPS (TTM)
- 1.98
- Dividend yield
- 1.09%
- 52-week range
- 48.52 – 86.00
- Beta
- 0.79
- Revenue (TTM)
- 708.53M
- Profit margin
- 21.02%
- Analyst target
- CHF 84.30
- Volume
- 12.14k
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bubendorf, Switzerland
- Employees
- 2,725
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.